Quarterly Changes To The Nasdaq Q-50 Index

/quotes/zigman/16652596/delayed/quotes/nls/sfm SFM -1.77% , Sears Holdings Corporation /quotes/zigman/95136/delayed/quotes/nls/shld SHLD +2.32% , Sina Corporation /quotes/zigman/82699/delayed/quotes/nls/sina SINA -2.18% , Ulta Salon, Cosmetics & Fragrance, Inc. /quotes/zigman/107036/delayed/quotes/nls/ulta ULTA +2.31% , Urban Outfitters, Inc. /quotes/zigman/55244/delayed/quotes/nls/urbn URBN +1.50% and Windstream Holdings, Inc. /quotes/zigman/21375738/delayed/quotes/nls/win WIN +1.21% . About NASDAQ OMX Global Indexes NASDAQ OMX Global Indexes has been creating innovative, market-leading, transparent indexes since 1971.
Source: http://www.marketwatch.com/story/quarterly-changes-to-the-nasdaq-q-50-index-2014-03-17

Lipocine to Begin Trading on the NASDAQ Capital Market

From 2000 to 2010, the Nasdaq listed more tech IPOs than the NYSE in every year except one, according to calculations by S&P Capital IQ. But in 2012, the NYSE managed to tie with Nasdaq; and in 2011 and 2013, the NYSE beat out Nasdaq for tech IPOs. NYSEs recent tech IPOs include the photo website Shutterstock Inc. /quotes/zigman/21382860/delayed /quotes/nls/fuel FUEL Whats at work here?
Source: http://blogs.marketwatch.com/thetell/2014/03/18/alibaba-is-the-latest-battle-in-war-of-nasdaq-v-nyse/

Alibaba is the latest battle in war of Nasdaq v. NYSE

The shares fell $.17 or 3.9 percent to $4.18. Elbit Medical Imaging Ltd. : Approximately 10,210,400 shares changed hands, a 2,070.1 percent increase over its 65-day average volume. The shares rose $.07 or 32.4 percent to $.27. Glen Burnie Bancorp : Approximately 5,700 shares changed hands, a 1,463.9 percent increase over its 65-day average volume.
Source: http://www.businessweek.com/ap/2014-03-18/nasdaq-stocks-posting-largest-volume-increases

Breadth buoys Nasdaq

(YHOO) topped the list of the days best performing components of the Nasdaq 100 index, trading up 4.0%. Year to date, Yahoo! has lost about 3.3% of its value. And the worst performing Nasdaq 100 component thus far on the day is Illumina (ILMN), trading down 2.1%. Illumina is showing a gain of 45.8% looking at the year to date performance. Two other components making moves today are Express Scripts Holding (ESRX), trading down 0.7%, and Biogen Idec (BIIB), trading up 4.0% on the day.
Source: http://www.forbes.com/sites/marketnewsvideo/2014/03/17/nasdaq-100-movers-ilmn-yhoo/

Nasdaq stocks posting see here largest percentage decreases

Oxygen Biotherap fell 8.5 percent to $5.68. Natures Sunshine fell 8.1 percent to $14.03. DTS Inc. fell 6.9 percent to $19.75.
Source: http://www.businessweek.com/ap/2014-03-18/nasdaq-stocks-posting-largest-percentage-decreases

Nasdaq stocks posting largest volume increases

Investors shouldnt fear Nasdaq 5,000. It is a very different index today, said James Paulsen, chief investment strategist, at Wells Capital Management in Minneapolis. I dont know whether it will break the old record high this year, but before this bull is over I believe it will. Investor psychology today is the polar opposite of what it was in 2000. Back then investors didnt care that companies had no earnings or much prospect for earnings.
Source: http://www.dallasnews.com/business/columnists/will-deener/20140316-breadth-buoys-nasdaq.ece

Nasdaq 100 Movers: ILMN, YHOO

Lipocine’s lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated for the prevention of preterm birth and is currently in Phase 1. Forward-Looking Statements The forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements relating to the Company’s expectations regarding increased awareness and visibility for the Company in the investment community and the clinical status and potential uses and benefits of Lipocine’s product candidates. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including without limitation, risks related to clinical trials, the receipt of regulatory approvals, market acceptance of our product candidates, manufacturing and commercialization risks, and other risks detailed in Lipocine’s filings with the U.S.
Source: http://finance.yahoo.com/news/lipocine-begin-trading-nasdaq-capital-123000003.html


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s